Search results for Abivax

Assembly Biosciences, Inc. (ASMB) Presents at ESCMID Global 2026 - Slideshow

Atea Pharmaceuticals: I'm Optimistic Ahead Of Critical HPV Catalyst

Brii Bio Presents Cross-Study Analysis of Post-Treatment HBsAg Rebound at APASL 2026

- Participants achieving HBsAg loss with pegylated interferon alfa (PEG-IFNα) ± elebsiran or BRII-179 demonstrated favorable off-treatment clinical outcomes, with most HBsAg reboun...

Avalo’s phase 2 skin disease win fuels pursuit of AbbVie despite placebo headwind

The placebo-adjusted result fell short of the bar set by Avalo, analysts and AbbVie’s rival program, but the biotech’s stock jumped in premarket trading.

GSK, Ionis unveil data for hepatitis B drug touted as ‘functional cure’

The findings supporting bepirovirsen were deemed a “historic moment” by physicians and validate a drug that has “clear blockbuster potential,” according to one analyst.

Avalo shares spike on skin drug data; BioNTech to cut staff

Avalo reported study success in what’s proven to be a tough-to-treat skin disease. Elsewhere, BioNTech announced plans to close multiple plants and Madrigal picked up an RNA-based...

May 28 2026 - AbbVie snags FDA’s first ADC approval for ultra-rare blood cancer

May 28 2026 - AbbVie snags FDA’s first ADC approval for ultra-rare blood cancer admin Thu, 05/28/2026 - 11:51 Steady progress across the board today, with new appro...

GSK’s hepatitis B drug cures one-fifth of patients in ‘major step’ for pervasive disease

GSK is pulling back the curtain on the phase 3 success of its chronic hepatitis B drug bepirovirsen, revealing that nearly one-fifth of all treated patients across two trials were...

Aligos sells China rights to HBV drug to hepatology player Amoytop in $445M deal

Aligos Therapeutics has secured a $25 million upfront fee from hepatology biopharma Amoytop in exchange for the China rights to its phase 2-stage chronic hepatitis B virus (HBV) tr...

INVIVYD

INVIVYD Anonymous (not verified) Wed, 04/29/2026 - 14:17 field_thread_url https://cafepharma.com/boards/threads/invivyd.703943/ board na...

ImmunityBio acquiring U.S. rights to Tokyo strain of BCG

<![CDATA[Haisco Enters $745 Million Exclusive License Agreement with AbbVie ]]>

Roivant Sciences Ltd. (ROIV) Discusses Brepocitinib Program Expansion and Phase III Batoclimab Data Update - Slideshow

ImmunityBio: Could Be One Approval Away From A Multi-Billion Dollar Breakout

Apogee Therapeutics: Targeting Atopic Dermatitis

Long-Term SHIV Suppression Using AAV Gene Therapy

Leronlimab is an antiviral HIV drug that targets and blocks the CCR5 receptor, thus blocking HIV’s ability to invade immune cells. Most macaques that produced sufficient number of...

<![CDATA[FDA Approves Idvynso for Treatment of HIV-1 Infection in Adults]]>

Sanofi immune drug hopeful posts mixed results in mid-stage tests

Lunsekimig, a bispecific drug aimed at two popular targets, succeeded in studies in asthma and nasal polyps but missed its mark in an eczema trial.

GSK plc (GSK) Discusses Bepirovirsen Phase III Data and Advances in Hepatitis B Treatment Transcript

Ipsen scuttles liver disease candidates from $952M Albireo acquisition

Ipsen has set aside the two drug candidates it picked up from a 2023 acquisition of liver disease specialist Albireo, with one of the assets discontinued entirely.

Gilead’s pipeline strategy in 2026: A broadening focus beyond HIV

We take a closer look at Gilead's pipeline strategy and dealmaking activity in 2026 as the company attempts to broaden its focus beyond HIV. The post Gilead’s pipeline strategy in...

<![CDATA[Boehringer Ingelheim Expands Immunology Pipeline With Preclinical Antibody Licensing Deal]]>

Chasing a tough-to-treat lung disease, Avalyn plans an IPO

Backed by Novo Holdings and multiple other prominent investors, the biotech is developing what it’s positioning as superior versions of entrenched — but flawed — medicines for idio...

<![CDATA[Biogen Enters $5.6 Billion Agreement to Acquire Apellis Pharmaceuticals ]]>